跳至主要内容
临床试验/CTRI/2010/091/000170
CTRI/2010/091/000170招募中4 期

An Observational Study to evaluate the safety and efficacy of Cetuximab in combination with platinum-based chemotherapy, in the first-line therapy of recurrent/ metastatic Squamous Cell Carcinoma of Head and Neck (SCCHN)

Merck Specialities Pvt Ltd5th Floor Shiv Sagar Estate, Dr. Aniie Besant Road, WorliMumbai 4000180 个研究点目标入组 100 人开始时间: 待定最近更新:

试验速览

阶段
4 期
状态
招募中
发起方
入组人数
100

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

入选标准

  • The study inclusion criteria is as per the local SPC: ?Cetuximab is indicated for the treatment of patients with squamous cell cancer of the head and neck in combination with platinum-based chemotherapy for recurrent and/or metastatic disease.?
  • For each platinum-based chemotherapy, the related product labels approved by India Health Authorities should also be followed strictly in terms of patient eligibility.

排除标准

  • Patients with known severe (grade 3 or 4; NCI-CTC) hypersensitivity reactions to
  • Cetuximab are contraindicated for Cetuximab

研究者

发起方
Merck Specialities Pvt Ltd5th Floor Shiv Sagar Estate, Dr. Aniie Besant Road, WorliMumbai 400018

相似试验

An Observational Study to evaluate the safety and... | 临床试验